Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 501–600 of 1,000
Current approaches for the treatment of multiple myeloma
Watanabe, R., Tokuhira, M., & Kizaki, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1294-z · Cited by 29
Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma
Mateos, M., Ocio, E. M., & Miguel, J. F. S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.005 · Cited by 29
“Moreover, treatment with lenalidomide/dexamethasone is associated with longer median OS (35 v 31 months) in spite of the fact that 42% of patients from the dexamethasone arm crossed over.(87,88) The activity of this regimen was independent of the number of lines of therapy, including transplant and previous use of tha…”
Self-citationJónsdóttir, G., Lund, S. H., Björkholm, M., Turesson, I., Wåhlin, A., Mailankody, S., Blimark, C. H., Hultcrantz, M. L., Porwit‐MacDonald, A., Landgren, O., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.134049 · Cited by 33
“The improved survival is considered to be primarily due to new treatment options in MM, including high-dose melphalan with autologous stem cell transplantation,(3) the immunomodulatory drugs and proteasome inhibitors.(4,5) Recently, second malignancies have gained great clinical and scientific attention in MM as three…”
BackgroundShould Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0495-9 · Cited by 29
Nielsen, T., Kristensen, S. R., Gregersen, H., Teodorescu, E. M., & Pedersen, S. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.03.015 · Cited by 32
Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
Grząśko, N., Morawska, M., & Hus, M. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.09.012 · Cited by 34
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 31
“A newer IMiD, lenalidomide, also showed positive results [33,34] and was approved for previously treated patients with MM in 2006.”
BackgroundImmunotherapy for the treatment of multiple myeloma
Jung, S., Lee, H., Vo, M.-C., Kim, H., & Lee, J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.011 · Cited by 30
A historical perspective on milestones in multiple myeloma research
Ribatti, D. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13003 · Cited by 29
Uy, G. L., Goyal, S. D., Fisher, N. M., Oza, A. Y., Tomasson, M. H., Stockerl-Goldstein, K. E., DiPersio, J. F., & Vij, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.384 · Cited by 30
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
“Since the introduction of lenalidomide for the treatment of RRMM patients [27,28,58], its use as induction or maintenance therapy in newly diagnosed MM has been rising [5,59].”
BackgroundVogl, D. T., Stadtmauer, E. A., Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Facon, T. T. F., Harousseau, J., Boral, A. L., Neuwirth, R., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07875.x · Cited by 30
Self-citationNovel Therapeutic Targets for Multiple Myeloma
Mahindra, A. K., Cirstea, D. D., & Raje, N. S. (2010) · Future Oncology · doi:10.2217/fon.10.2 · Cited by 29
“The addition of lenalidomide to highdose dexamethasone (40 mg four-times per week for 3 weeks) in relapsed/refractory MM patients induces a 61% ORR with a median TTP of 11 months [9].”
BackgroundKleber, M., Ihorst, G., Udi, J., Koch, B., Wäsch, R., & Engelhardt, M. M. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.09.216 · Cited by 28
Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma
Undas, A., Usnarska‐Zubkiewicz, L., Helbig, G., Woszczyk, D., Kozińska, J., Dmoszyńska, A., Podolak‐Dawidziak, M., & Kuliczkowski, K. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12269 · Cited by 28
Bhutani, D., Zonder, J. A., Valent, J. N., Tageja, N., Ayash, L. J., Deol, A., Al-Kadhimi, Z. S., Abrams, J., Lum, L. G., Ratanatharathorn, V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1808-5 · Cited by 29
How lenalidomide is changing the treatment of patients with multiple myeloma
Dimopoulos, M. A., Terpos, E., & Niesvizky, R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.013 · Cited by 29
“However, when enalidomide is combined with dexamethasone the reported ncidence of grade≥3 VTE is 11–15% in RRMM patients not iven thromboprophylaxis [27,35] and 23–26% in patients ith NDMM [61,62].”
BackgroundMethodInfluentialSelf-citationTriplet vs. doublet drug regimens for managing multiple myeloma
Offidani, M., Corvatta, L., & Gentili, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1418856 · Cited by 28
“Two randomized phase III trials [48,49] have shown the superiority of lenalidomide with the addition of dexamethasone compared to dexamethasone single agent.”
BackgroundLeleu, X. P., Gay, F., Flament, A., Allcott, K., & Delforge, M. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3191-7 · Cited by 29
“reductions or interruptions due to any adverse event (AE) were recorded in 76% of patients [41].”
BackgroundDimopoulos, M. A., Kaufman, J. L., White, D. J., Cook, G., Rizzo, M., Xu, Y., Fahrbach, K. R., Gaudig, M., Slavcev, M., Dearden, L., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.011 · Cited by 31
Self-citationMultiple myeloma: management of adverse events
Gay, F., & Palumbo, A. (2009) · Medical Oncology · doi:10.1007/s12032-009-9262-4 · Cited by 27
Profile of elotuzumab and its potential in the treatment of multiple myeloma
van Rhee, F., Liu, Y., & Szmania, S. M. (2014) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s49780 · Cited by 27
“3 months were noted, respectively.(46,47) A dose of 10 mg/kg elotuzumab was chosen for subsequent Phase III trials.”
Quach, H., Fernyhough, L. J., Henderson, R. A., Corbett, G., Baker, B., Browett, P., Blacklock, H. A., Forsyth, C. J., Underhill, C. R., Cannell, P., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14562 · Cited by 27
Self-citationERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 29
Frenzel, L., Decaux, O., Macro, M., Belhadj‐Merzoug, K., Manier, S., Touzeau, C., Leleu, X. P., Frère, C., Lecompte, T., Perrot, A., et al. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.11.021 · Cited by 28
Current and Emerging Treatment Options for Patients with Relapsed Myeloma
Castelli, R., Gualtierotti, R., Orofino, N., Losurdo, A., Gandolfi, S., & Cugno, M. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8014 · Cited by 31
Yhim, H.-Y., Kım, K., Kim, J. S., Kang, H. J., Kim, J.-A., Min, C.-K., Bae, S. H., Park, E., Yang, D.-H., Suh, C., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.164 · Cited by 28
Pallotti, M. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.7049 · Cited by 27
Treating venous thromboembolism in patients with cancer
Piatek, C. I., O'Connell, C. L., & Liebman, H. A. (2012) · Expert Review of Hematology · doi:10.1586/ehm.11.86 · Cited by 28
Montefusco, V., Galli, M., Spina, F., Stefanoni, P., Mussetti, A., Perrone, G., Philippis, C. D., Dalto, S. C., Maura, F., Bonini, C., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.914203 · Cited by 27
Liu, T., Guo, F., Zhu, X., He, X., & Xie, L. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5209 · Cited by 36
“Lenalidomide has also been assessed in two phase III registration clinical trials (MM-009 and MM-010) (80,81).”
Bertino, E. M., McMichael, E. L., Mo, X. M., Trikha, P., Davis, M. E., Paul, B. K., Grever, M. R., Carson, W. E., & Otterson, G. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0879 · Cited by 32
“Initial trials leading to drug approval in the United State reported thrombosis in up to 10% of multiple myeloma patients treated with lenalidomide and dexamethasone (6, 7).”
BackgroundIxazomib: a novel drug for multiple myeloma
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1518129 · Cited by 30
Management of Relapsed and Relapsed/Refractory Multiple Myeloma
Laubach, J. P., Mitsiades, C. S., Mahindra, A. K., Luskin, M. R., Rosenblatt, J. M., Ghobrial, I. M., Schlossman, R. L., Avigan, D., Raje, N. S., Munshi, N. C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0098 · Cited by 27
Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
Salomon‐Perzyński, A., Jamroziak, K., & Głodkowska‐Mrówka, E. (2021) · Diagnostics · doi:10.3390/diagnostics11091534 · Cited by 29
Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 29
“Lenalidomide also induces marked responses and substantially prolongs survival in refractory myeloma when given with glucocorticoids (Dimopoulos et al., 2007; Weber et al., 2007).”
BackgroundSiegel, D. S. D. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713511176 · Cited by 26
Oehrlein, K., Langer, C., Sturm, I., Pönisch, W., Hahn‐Ast, C., Kuhn, S., & Weisel, K. C. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.01.001 · Cited by 26
Total cost comparison in relapsed/refractory multiple myeloma
Durie, B. G. M., Binder, G., Pashos, C. L., Khan, Z. M., Hussein, M. A., & Borrello, I. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.760159 · Cited by 26
McCurdy, A. B. R., & Lacy, M. Q. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713480155 · Cited by 28
Lenalidomide: A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
Scott, L. J., & Lyseng-Williamson, K. A. (2011) · Drugs · doi:10.2165/11206420-000000000-00000 · Cited by 27
“Within each trial, there were no significant between-group differences in the demographics and disease activity/health status of patients at baseline.([41,42])”
InfluentialKowalewski, D. J., Walz, J. S., Backert, L., Schuster, H., Kohlbacher, O., Weisel, K. C., Rittig, S. M., Kanz, L., Salih, H. R., Rammensee, H., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.14 · Cited by 27
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 30
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
Lee, D. H., & Fradley, M. G. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0618-y · Cited by 27
Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengaß, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K. C., Salwender, H. J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1486356 · Cited by 28
Mikhael, J. R., Manola, J. B., Dueck, A. C., Hayman, S. R., Oettel, K. R., Kanate, A. S., Lonial, S., & Rajkumar, S. V. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0110-7 · Cited by 27
Tabchi, S., Nair, R., Kunacheewa, C., Patel, K. K., Lee, H. C., Thomas, S. K., Amini, B., Ahmed, S., Mehta, R. S., Bashir, Q., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.05.001 · Cited by 29
Byun, J. M., Yoon, S., Koh, Y., Kim, I., Jo, J., Park, H., Lee, J., & Lee, J. (2019) · Anticancer Research · doi:10.21873/anticanres.13712 · Cited by 27
Current Treatment for Multiple Myeloma
Avigan, D., & Rosenblatt, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1407442 · Cited by 26
Targeted Therapy of Multiple Myeloma
Dolloff, N. G., & Talamo, G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_9 · Cited by 26
Current therapeutic strategies for multiple myeloma
Torimoto, Y., Shindo, M., Ikuta, K., & Kohgo, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0826-3 · Cited by 27
“Recently, the development of novel molecular targeting agents such as thalidomide, lenalidomide and bortezomib has demonstrated a significant survival advantage compared with conventional chemotherapies [6–8].”
BackgroundSalomon‐Perzyński, A., Walter‐Croneck, A., Usnarska‐Zubkiewicz, L., Dytfeld, D., Zielińska, P., Wojciechowska, M., Hołojda, J., Robak, P. J., Pasternak, A., Knopińska‐Posłuszny, W., et al. (2019) · Advances in Medical Sciences · doi:10.1016/j.advms.2019.05.001 · Cited by 26
Robinson, R. M., Reyes, L., Duncan, R. M., Bian, H., Strobel, E. D., Hyman, S. L., Reitz, A. B., & Dolloff, N. G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111906 · Cited by 27
Management of disease- and treatment-related complications in patients with multiple myeloma
Gay, F., & Palumbo, A. (2010) · Medical Oncology · doi:10.1007/s12032-010-9542-z · Cited by 25
“In relapsed patients treated with the RD regimen, incidence of grades 3–4 thrombocytopenia was 10–12% [19, 20]: incidence was higher in patients with impaired renal function [26].”
BackgroundInfluentialWaxman, A. J., Kuehl, M. W., Balakumaran, A., Weiss, B. M., & Landgren, O. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.053 · Cited by 26
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
“Based on these promising findings, two large randomized phase 3 studies were initiated, one in North America (MM-009; NCT00056160) [26] and one in Europe, Australia, and Israel (MM-010; NCT00424047) [27].”
BackgroundSelf-citationTan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 26
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 26
“of IMiDs is associated with neutropenia, thrombocytopenia, bone marrow failure and stem cell mobilization.(9,11,12) In addition, there is a concern of an increased risk”
BackgroundManagement of older patients with multiple myeloma
Gay, F., & Palumbo, A. P. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.10.003 · Cited by 27
“lenalidomide, and lenalidomide has been administered to patients who have received prior thalidomide treatment without further deterioration of preexisting thalidomide-related neuropathy.(42,43) To date, there are no pharmacological drugs able to effectively relieve neuropathic symptoms, and modifying promptly the sch…”
BackgroundThe potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma
Altenburg, J. D., & Farag, S. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.993753 · Cited by 28
Lee, S., Lim, J., Ryu, D., Kim, T., Yoon, J., Cho, B., Eom, K., Kim, Y., Kim, H., Lee, S., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1861-2 · Cited by 27
“Considering the time to first response in prior clinical trials, sample time points were decided [4, 5].”
BackgroundRichardson, P. G. G., Laubach, J. P., Mitsiades, C. S., Schlossman, R. L., Hideshima, T., Redman, K., Chauhan, D., Ghobrial, I. M., Munshi, N. C., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08791.x · Cited by 29
Caballero, D. M., Campo, E., López‐Guillermo, A., Martín, A., Arranz-Sáez, R., Giné, E., López, A., González-Barca, E. M., Canales, M. Á., González, M., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1783-4 · Cited by 27
“Lenalidomide has proven activity in relapsed or refractory multiple myeloma when given in combination with other drugs such as dexamethasone [152] or as a single-agent therapy in aggressive NHL [153].”
BackgroundRichardson, P. G. G., Harvey, R. D., Laubach, J. P., Moreau, P., Lonial, S., & Miguel, J. F. S. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1096773 · Cited by 24
“Two Phase 3 studies comparing lenalidomide and dexamethasone (LEN-Dex) with Pbo-Dex (MM-009 and MM-010) showed marked improvement in clinical benefit with LEN-Dex, prompting the US FDA approval of LEN-Dex for the treatment of patients with MM with ≥1 prior line of therapy.[42,43] More recently, the Phase 3 ASPIRE tria…”
BackgroundSelf-citationHájek, R., Jarkovský, J., Maisnar, V., Pour, L., Špıčka, I., Minařík, J., Gregora, E., Kessler, P., Sýkora, M., Fraňková, H., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.04.003 · Cited by 24
Therapy of Relapsed and Refractory Multiple Myeloma
Moehler, T. M., & Goldschmidt, H. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_11 · Cited by 27
McMillin, D. W., Delmore, J. E., Negri, J. M., Buon, L., Jacobs, H. M., Laubach, J. P., Jakubíková, J., Ooi, M. G. M., Hayden, P. J., Schlossman, R. L., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08427.x · Cited by 25
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2011) · Expert Review of Hematology · doi:10.1586/ehm.10.83 · Cited by 25
Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide
Chen, H., Fu, S., Feng, N., Chen, H., Gao, Y., Zhao, Y.-J., Xue, H., Zhang, Y., Li, X., Dai, J., et al. (2016) · Medicine · doi:10.1097/md.0000000000004606 · Cited by 25
Hari, P., Mateos, M., Abonour, R., Knop, S. T., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D. S. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.122 · Cited by 24
Jung, S., Lee, S., Lee, M., Kim, S., Yim, S., Kim, T., Min, C., & Chung, Y. (2017) · Haematologica · doi:10.3324/haematol.2017.168070 · Cited by 24
“A recent genomewide association study provided evidence of common genetic susceptibility to immunoglobulin light chain amyloidosis and MM, in which some significant SNPs were mapped in RNA genes or miRNAs known to be associated with organ involvement in MM,12 suggesting the importance of exploring gene-regulatory mech…”
BackgroundInfluentialRi, M., Suzuki, K., Iida, S., Hatake, K., Chou, T., Taniwaki, M., Watanabe, N., & Tsukamoto, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9567-17 · Cited by 24
“The main treatment regimens that are preferred for relapsed or refractory multiple myeloma (RRMM) include proteasome inhibitors (PIs) (3-5) and/or immunomodulatory drugs (IMiDs) (5-7).”
BackgroundClinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas, S., Pukrop, T., Hackl, C., Herr, W., Ghibelli, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01357 · Cited by 24
CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
Benson, D. M., & Byrd, J. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4061 · Cited by 23
“1 months.(30,31) In the APEX (Assessment of Proteosome Inhibition for Extending Remissions) trial, the objective response rate for bortezomib was 38%, with median TTP of 6.”
BackgroundLuo, X., Du, X., Li, J.-L., Liu, X., & Meng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s166640 · Cited by 23
Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
Reece, D. E., Kouroukis, C. T., LeBlanc, R., Sébag, M., Song, K., & Ashkenas, J. (2012) · Advances in Hematology · doi:10.1155/2012/621958 · Cited by 23
“…University Health Network, 610 University Avenue, Toronto, ON, Canada M5G 2M9 2 Department of Oncology, Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON, Canada L8V 5C2 3 Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, QC, Canada H1T 2M4 4 McGill University Health…”
Dimopoulos, M. A., Hussein, M. A., Swern, A. S., & Weber, D. (2011) · Leukemia · doi:10.1038/leu.2011.126 · Cited by 23
Self-citationRisk and management of thrombosis in multiple myeloma
Leebeek, F. W. G., Kruip, M. J. H. A., & Sonneveld, P. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70024-5 · Cited by 23
“5% [17].”
Sanborn, S. L., Gibbons, J., Krishnamurthi, S., Brell, J. M., Dowlati, A., Bokar, J. A., Nock, C. J., Horvath, N., Bako, J., Remick, S. C., et al. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9200-x · Cited by 23
Changing paradigms in the treatment of multiple myeloma
Bladé, J., & Rosiñol, L. (2009) · Haematologica · doi:10.3324/haematol.2008.002766 · Cited by 23
Bridoux, F., Chen, N., Moreau, S., Arnulf, B., Moumas, É., Abraham, J., Desport, É., Jaccard, A., & Fermand, J. P. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3068-9 · Cited by 27
Multiple Myeloma Minimal Residual Disease
Paiva, B., García‐Sánz, R., & Miguel, J. F. S. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_7 · Cited by 27
Self-citationAllegra, A., Innao, V., Basile, G., Pugliese, M., Allegra, A. G., Pulvirenti, N., & Musolino, C. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1738213 · Cited by 24
Brown, S., Pawlyn, C., Tillotson, A., Sherratt, D., Flanagan, L. M., Low, E., Morgan, G. J., Williams, C. D., Kaiser, M., Davies, F. E., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.019 · Cited by 23
Zhou, L., Hou, J., Fu, W., Wang, D., Yuan, Z., & Jiang, H. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.03.039 · Cited by 23
Qiao, S.-K., Guo, X., Ren, J., & Ren, H. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156134 · Cited by 28
“[12,17,18] In addition, lenalidomide has been shown to further increase the risk of adverse events (AEs), especially when combined with glucocorticoids and/or cytotoxic drugs.[12,15,16,19,20]”
BackgroundResultInfluentialRaje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Advances in Supportive Care for Multiple Myeloma
Raje, N. S., Yee, A. J., & Roodman, G. D. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0055 · Cited by 22
Ocio, E. M., Mateos, M., & Miguel, J. F. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.691164 · Cited by 22
“Although the clinical activity of thalidomide [64,65] and lenalidomide [66-68] in MM has already been demonstrated, the precise mechanism of action of IMIDs has not yet been well established.”
BackgroundSelf-citationLenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo
Jinesh, G. G., Lee, E. K., Tran, J., & Kamat, A. M. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.05.007 · Cited by 23
“Furthermore, lenalidomide has been shown to be effective in 2 separate phase III clinical trials for relapsing multiple myeloma demonstrating improved time to progression and overall survival [13,14].”
BackgroundCereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Hesterberg, R. S., Beatty, M. S., Han, Y., Fernandez, M. R., Akuffo, A. A., Goodheart, W. E., Yang, C., Chang, S., Colin, C., Alontaga, A. Y., et al. (2020) · Blood · doi:10.1182/blood.2019003257 · Cited by 22
Prognosis analysis of necroptosis-related genes in colorectal cancer based on bioinformatic analysis
Liang, X., Cheng, Z., Chen, X., & Li, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.955424 · Cited by 23
“Lenalidomide is usually used in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (Dimopoulos et al., 2007).”
BackgroundBriani, C., Torre, C. D., Campagnolo, M., Lucchetta, M., Berno, T., Candiotto, L., Padua, L., Ermani, M., Cavaletti, G., & Zambello, R. (2013) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12002 · Cited by 24
Giannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 30
Alegre, A. M., Aguado, B., Giraldo, P., Ríos, E., Cánovas, A., Ibáñez, Á., Castillo, I., Hernández, M., Oriol, A., Palomera, L., et al. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0785-z · Cited by 23
“The heterogeneity of the patients in our study makes it difficult to compare with those from the pivotal phase III clinical trials of lenalidomide [8–12].”
BackgroundResultInfluentialThe role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance
Chen, R., Zhao, H., Wu, D., Zhao, C., Zhao, W., & Zhou, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12231 · Cited by 22
“It is characterized by the clonal expansion of malignant plasma cells [1] and remains largely incurable in spite of the advent of several therapeutic strategies [2].”
BackgroundMey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 23
“Treatment with Rd results in a time to progression (TTP) of 17 1 months for patients with only one prior line of therapy, and a TTP of 10 6 months for patients having received two or more prior therapies, respectively (Dimopoulos et al, 2007; Weber et al, 2007; Stadtmauer et al, 2009).”
BackgroundResultTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 26
Chan, H. S. H., & Milne, R. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16238 · Cited by 23
“Other factors contributing to the improved survival could include better supportive care (Thorsteinsdottir et al , 2018) and funding of lenalidomide in 2014 in the relapsed setting (Dimopoulos et al , 2007; Dimopoulos et al , 2009).”
Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 25
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.